Clinical & Trials
Electronic Patient-Reported Outcome(ePRO)
In one line
A patient-reported outcome instrument administered and captured electronically, subject to validation and 21 CFR Part 11 data-integrity requirements when used in FDA-regulated trials.
Definition
ePRO refers to the electronic capture of patient-reported outcome data, such as symptom diaries, quality-of-life questionnaires, or pain scales, using tablets, smartphones, web portals, or other electronic systems instead of paper forms. FDA's 2009 guidance on patient-reported outcome measures, and subsequent methodology discussion papers, describe expectations for developing a PRO instrument's content validity and for demonstrating that migrating an existing paper instrument to an electronic modality does not change how patients interpret or respond to it, an activity commonly called equivalence or migration testing. When ePRO data are used to support a medical product labeling claim or a device's clinical evidence, the electronic system that captures, stores, and transmits the data must comply with 21 CFR Part 11 requirements for electronic records and electronic signatures, including audit trails, access controls, and record retention.
Why it matters
ePRO adoption has grown alongside decentralized and hybrid clinical trials, since electronic capture reduces missing data and enables real-time compliance monitoring, but it also raises data integrity questions that regulators scrutinize during inspection. ICH E6(R3), the revised Good Clinical Practice guideline, expands expectations for data governance, including for data generated through electronic patient-facing systems, aligning international expectations with FDA's Part 11 framework.
Common pitfalls
- •Migrating a paper PRO instrument to a tablet or app without conducting equivalence testing, which can invalidate the instrument's established measurement properties.
- •Deploying an ePRO platform that lacks a compliant audit trail or that allows undocumented edits to submitted patient responses, creating a Part 11 data integrity finding.
- •Assuming ePRO always improves compliance; poor usability or connectivity gaps in a decentralized trial can increase missing data if the platform is not tested with the intended patient population.
Sources